Home ETF List About

Portfolio Holdings Detail for ISIN IE00BYZK4776
Stock Name / FundiShares Healthcare Innovation UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares IV Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300ZP07LMR36K1T02
ETF TickerDRDR(GBX) LSE
ETF Ticker2B78(EUR) F
ETF Ticker2B78.DE(EUR) CXE
ETF TickerDRDR.LS(GBX) CXE
ETF TickerHEAL.AS(EUR) CXE
ETF TickerHEAL.LS(USD) CXE
ETF TickerHEALz(USD) CXE
ETF TickerHEAL(EUR) ETF Plus
ETF TickerDRDR.L(GBP) LSE

Holdings detail for JANX

Stock NameJanux Therapeutics Inc
TickerJANX(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS47103J1051

Show aggregate JANX holdings

News associated with JANX

Stifel Nicolaus Reiterates Buy Rating for Janux Therapeutics (NASDAQ:JANX)
Stifel Nicolaus restated their buy rating on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a research report report published on Wednesday, Marketbeat Ratings reports. Stifel Nicolaus currently has a $45.00 price target on the stock. Other research analysts have also recently issued research reports about the company. Piper Sandler assumed coverage on Janux […] - 2025-09-11 04:40:25
The Math Shows SCHA Can Go To $31
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 09:07:38
Y Intercept Hong Kong Ltd Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
Y Intercept Hong Kong Ltd acquired a new position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund acquired 17,833 shares of the company’s stock, valued at approximately $481,000. Other hedge funds and other institutional […] - 2025-07-28 06:14:50
Janux Therapeutics (NASDAQ:JANX) Research Coverage Started at Raymond James Financial
Raymond James Financial started coverage on shares of Janux Therapeutics (NASDAQ:JANX – Free Report) in a report released on Friday, MarketBeat.com reports. The brokerage issued an outperform rating and a $65.00 price target on the stock. Janux Therapeutics Price Performance Janux Therapeutics stock opened at $25.15 on Friday. The firm has a market capitalization of […] - 2025-07-14 03:46:45
KBC Group NV Makes New $66,000 Investment in Janux Therapeutics, Inc. (NASDAQ:JANX)
KBC Group NV acquired a new position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 2,461 shares of the company’s stock, valued at approximately $66,000. Other hedge funds and […] - 2025-07-09 04:33:52
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of “Buy” by Brokerages
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been assigned an average rating of “Buy” from the eleven analysts that are covering the stock, Marketbeat reports. One investment analyst has rated the stock with a hold rating, eight have assigned a buy rating and two have assigned a strong buy rating to […] - 2025-06-26 04:34:55
Exchange Traded Concepts LLC Increases Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
Exchange Traded Concepts LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 20.4% during the first quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 4,043 shares of the company’s stock after buying an additional 686 shares during the period. Exchange Traded […] - 2025-06-25 04:56:58
SG Americas Securities LLC Takes Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
SG Americas Securities LLC purchased a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) during the first quarter, Holdings Channel reports. The fund purchased 28,631 shares of the company’s stock, valued at approximately $773,000. Other hedge funds have also recently made changes to their positions in the company. Russell Investments Group […] - 2025-06-20 05:12:52
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC
UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 532.7% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 165,737 shares of the company’s […] - 2025-06-01 05:33:05
Two Sigma Investments LP Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
Two Sigma Investments LP lessened its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 22.3% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 59,974 shares of the company’s stock after selling 17,218 shares during the […] - 2025-05-30 04:50:55
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Purchased by Squarepoint Ops LLC
Squarepoint Ops LLC grew its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 155.1% during the fourth quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,176 shares of the company’s stock after purchasing an additional 25,034 shares during the period. […] - 2025-05-29 05:18:55
ProShare Advisors LLC Purchases 2,003 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
ProShare Advisors LLC increased its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 23.9% during the 4th quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 10,384 shares of the company’s stock after acquiring an additional 2,003 shares during the quarter. ProShare […] - 2025-05-26 05:19:11
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Average Rating of “Buy” by Analysts
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has earned an average recommendation of “Buy” from the eleven brokerages that are presently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the […] - 2025-05-20 02:39:02
Deutsche Bank AG Has $4.98 Million Stock Position in Janux Therapeutics, Inc. (NASDAQ:JANX)
Deutsche Bank AG raised its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 386.6% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 93,029 shares of the company’s stock after acquiring an additional 73,912 shares during the quarter. Deutsche Bank AG’s […] - 2025-05-19 04:55:22
Northern Trust Corp Purchases 42,302 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
Northern Trust Corp boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 15.9% in the fourth quarter, HoldingsChannel.com reports. The institutional investor owned 308,800 shares of the company’s stock after acquiring an additional 42,302 shares during the quarter. Northern Trust Corp’s holdings in Janux Therapeutics were worth $16,533,000 as of its most […] - 2025-05-15 04:54:52
Janux Therapeutics (NASDAQ:JANX) Shares Gap Down After Insider Selling
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) shares gapped down prior to trading on Monday after an insider sold shares in the company. The stock had previously closed at $32.88, but opened at $30.00. Janux Therapeutics shares last traded at $30.73, with a volume of 453,943 shares changing hands. Specifically, insider Andrew Hollman Meyer […] - 2025-05-07 02:20:58
Tower Research Capital LLC TRC Purchases 3,436 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
Tower Research Capital LLC TRC boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 878.8% in the fourth quarter, according to its most recent filing with the SEC. The institutional investor owned 3,827 shares of the company’s stock after purchasing an additional 3,436 shares during the period. Tower Research Capital LLC TRC’s […] - 2025-05-06 05:08:51
128,062 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Acquired by First Trust Advisors LP
First Trust Advisors LP purchased a new stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the 4th quarter, according to its most recent filing with the SEC. The fund purchased 128,062 shares of the company’s stock, valued at approximately $6,856,000. Several other hedge funds have also made changes to their positions in JANX. […] - 2025-04-30 05:52:59
Marshall Wace LLP Sells 25,703 Shares of Janux Therapeutics, Inc. (NASDAQ:JANX)
Marshall Wace LLP trimmed its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 53.5% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 22,348 shares of the company’s stock after selling 25,703 shares during the quarter. Marshall Wace LLP’s holdings […] - 2025-04-30 05:04:57
Brokerages Set Janux Therapeutics, Inc. (NASDAQ:JANX) PT at $95.25
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) has been given an average recommendation of “Buy” by the eleven analysts that are currently covering the stock, Marketbeat reports. One research analyst has rated the stock with a hold rating, eight have issued a buy rating and two have assigned a strong buy rating to the […] - 2025-04-28 02:39:12
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Barclays PLC
Barclays PLC boosted its holdings in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 51.7% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 263,970 shares of the company’s stock after purchasing an additional 89,909 shares during the period. […] - 2025-04-21 05:38:44
Orion Portfolio Solutions LLC Has $263,000 Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)
Orion Portfolio Solutions LLC trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 25.6% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 4,913 shares of the company’s stock after selling 1,692 shares during the quarter. Orion Portfolio Solutions LLC’s […] - 2025-04-10 05:45:05
9,378 Shares in Janux Therapeutics, Inc. (NASDAQ:JANX) Purchased by Sei Investments Co.
Sei Investments Co. acquired a new stake in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) in the fourth quarter, according to the company in its most recent filing with the SEC. The firm acquired 9,378 shares of the company’s stock, valued at approximately $502,000. Several other large investors also recently added to or […] - 2025-04-10 04:18:49
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Bought by Franklin Resources Inc.
Franklin Resources Inc. grew its stake in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 2,519.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 497,287 shares of the company’s stock after purchasing an additional 478,304 shares during the quarter. Franklin Resources Inc. […] - 2025-04-07 06:11:08
Janux Therapeutics, Inc. (NASDAQ:JANX) Shares Sold by Corebridge Financial Inc.
Corebridge Financial Inc. trimmed its position in shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 7.0% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 13,940 shares of the company’s stock after selling 1,053 shares during the period. Corebridge […] - 2025-04-07 04:32:49
Janux Therapeutics, Inc. (NASDAQ:JANX) Receives $92.44 Consensus Target Price from Analysts
Shares of Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report) have been given a consensus rating of “Buy” by the twelve analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation, nine have given a buy recommendation and two have issued a strong buy recommendation on […] - 2025-04-03 02:36:47
Bank of New York Mellon Corp Lowers Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
Bank of New York Mellon Corp trimmed its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 9.2% in the fourth quarter, Holdings Channel.com reports. The institutional investor owned 78,859 shares of the company’s stock after selling 7,976 shares during the quarter. Bank of New York Mellon Corp’s holdings in Janux Therapeutics were worth […] - 2025-03-19 05:08:43
Victory Capital Management Inc. Boosts Stock Holdings in Janux Therapeutics, Inc. (NASDAQ:JANX)
Victory Capital Management Inc. boosted its position in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 715.0% in the fourth quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 242,409 shares of the company’s stock after buying an additional 212,664 shares during the quarter. Victory Capital Management […] - 2025-03-13 06:32:52
Janux Therapeutics (NASDAQ:JANX) Hits New 12-Month Low After Analyst Downgrade
Janux Therapeutics, Inc. (NASDAQ:JANX – Get Free Report)’s stock price reached a new 52-week low during trading on Monday after Scotiabank lowered their price target on the stock from $62.00 to $41.00. Scotiabank currently has a sector perform rating on the stock. Janux Therapeutics traded as low as $31.67 and last traded at $31.68, with […] - 2025-03-05 04:54:56
New York State Common Retirement Fund Has $855,000 Stake in Janux Therapeutics, Inc. (NASDAQ:JANX)
New York State Common Retirement Fund increased its holdings in Janux Therapeutics, Inc. (NASDAQ:JANX – Free Report) by 84.6% in the fourth quarter, Holdings Channel reports. The institutional investor owned 15,964 shares of the company’s stock after buying an additional 7,318 shares during the period. New York State Common Retirement Fund’s holdings in Janux Therapeutics […] - 2025-03-04 06:34:50

iShares Healthcare Innovation UCITS ETF USD (Acc) JANX holdings

DateNumber of JANX Shares HeldBase Market Value of JANX SharesLocal Market Value of JANX SharesChange in JANX Shares HeldChange in JANX Base ValueCurrent Price per JANX Share HeldPrevious Price per JANX Share Held
2025-11-11 (Tuesday)68,068USD 1,965,123JANX holding increased by 87127USD 1,965,1230USD 87,127 USD 28.87 USD 27.59
2025-11-10 (Monday)68,068USD 1,877,996JANX holding increased by 75555USD 1,877,9960USD 75,555 USD 27.59 USD 26.48
2025-11-07 (Friday)68,068USD 1,802,441JANX holding decreased by -148388USD 1,802,4410USD -148,388 USD 26.48 USD 28.66
2025-11-06 (Thursday)68,068USD 1,950,829JANX holding increased by 76236USD 1,950,8290USD 76,236 USD 28.66 USD 27.54
2025-11-05 (Wednesday)68,068USD 1,874,593JANX holding increased by 36076USD 1,874,5930USD 36,076 USD 27.54 USD 27.01
2025-11-04 (Tuesday)68,068USD 1,838,517JANX holding decreased by -24504USD 1,838,5170USD -24,504 USD 27.01 USD 27.37
2025-11-03 (Monday)68,068USD 1,863,021JANX holding decreased by -91211USD 1,863,0210USD -91,211 USD 27.37 USD 28.71
2025-10-31 (Friday)68,068USD 1,954,232JANX holding increased by 13613USD 1,954,2320USD 13,613 USD 28.71 USD 28.51
2025-10-30 (Thursday)68,068USD 1,940,619JANX holding increased by 47648USD 1,940,6190USD 47,648 USD 28.51 USD 27.81
2025-10-29 (Wednesday)68,068USD 1,892,971JANX holding decreased by -132733USD 1,892,9710USD -132,733 USD 27.81 USD 29.76
2025-10-28 (Tuesday)68,068USD 2,025,704JANX holding increased by 164044USD 2,025,7040USD 164,044 USD 29.76 USD 27.35
2025-10-27 (Monday)68,068USD 1,861,660JANX holding increased by 166767USD 1,861,6600USD 166,767 USD 27.35 USD 24.9
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of JANX by Blackrock for IE00BYZK4776

Show aggregate share trades of JANX

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-10-24SELL-58024.90025.190 25.161USD -14,593 33.54 Profit of 4,859 on sale
2025-09-11BUY29125.12025.130 25.129USD 7,313 34.62
2025-07-08SELL-29024.45024.650 24.630USD -7,143 35.48 Profit of 3,147 on sale
2025-06-24SELL-29223.35024.186 24.102USD -7,038 36.24 Profit of 3,545 on sale
2025-06-23SELL-29222.88024.070 23.951USD -6,994 36.34 Profit of 3,618 on sale
2025-06-20BUY24,05323.60023.910 23.879USD 574,362 36.43
2025-06-11SELL-19225.46026.980 26.828USD -5,151 37.10 Profit of 1,973 on sale
2025-05-30SELL-19223.80024.265 24.218USD -4,650 37.88 Profit of 2,623 on sale
2025-05-21BUY19224.77025.510 25.436USD 4,884 38.68
2025-05-14SELL-1,14622.62025.960 25.626USD -29,367 39.22 Profit of 15,576 on sale
2025-04-30SELL-19133.20033.510 33.479USD -6,394 40.30 Profit of 1,304 on sale
2025-04-28SELL-19132.23032.380 32.365USD -6,182 40.46 Profit of 1,547 on sale
2025-04-25SELL-19131.05031.920 31.833USD -6,080 40.56 Profit of 1,667 on sale
2025-04-11SELL-1,09828.80028.900 28.890USD -31,721 41.50 Profit of 13,849 on sale
2025-04-08SELL-54623.79025.630 25.446USD -13,894 42.04 Profit of 9,062 on sale
2025-04-07SELL-39624.38025.620 25.496USD -10,096 42.25 Profit of 6,634 on sale
2025-03-31SELL-36427.00028.130 28.017USD -10,198 42.99 Profit of 5,452 on sale
2025-03-21SELL-36229.94030.560 30.498USD -11,040 44.00 Profit of 4,888 on sale
2025-03-12SELL-18431.81031.980 31.963USD -5,881 45.31 Profit of 2,456 on sale
2025-02-28SELL-18432.89033.300 33.259USD -6,120 47.20 Profit of 2,566 on sale
2025-02-25BUY18332.69033.400 33.329USD 6,099 47.97
2025-02-20SELL-18337.17037.900 37.827USD -6,922 48.64 Profit of 1,979 on sale
2025-02-19BUY36637.33037.540 37.519USD 13,732 48.85
2025-02-18BUY18337.09038.130 38.026USD 6,959 49.07
2024-12-30BUY1,24752.50053.710 53.589USD 66,825 53.38
2024-12-06SELL-17464.99068.990 68.590USD -11,935 52.42 Loss of -2,814 on sale
2024-12-04SELL-52266.83570.030 69.710USD -36,389 51.41 Loss of -9,554 on sale
2024-11-21SELL-17646.50049.780 49.452USD -8,704 53.04 Profit of 631 on sale
2024-11-20SELL-17948.96049.340 49.302USD -8,825 53.27 Profit of 710 on sale
2024-11-19SELL-17949.01049.735 49.663USD -8,890 53.52 Profit of 690 on sale
2024-11-18SELL-70048.12049.140 49.038USD -34,327 53.85 Profit of 3,371 on sale
2024-11-12SELL-17452.84054.950 54.739USD -9,525 53.92 Loss of -142 on sale
2024-11-07SELL-17454.21056.500 56.271USD -9,791 53.90 Loss of -413 on sale
2024-11-05SELL-34855.28056.140 56.054USD -19,507 53.68 Loss of -825 on sale
2024-10-28SELL-17454.36054.840 54.792USD -9,534 52.35 Loss of -425 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of JANX

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19172,634103260,40266.3%
2025-09-18176,5350269,33765.5%
2025-09-17128,85960187,77068.6%
2025-09-16100,2950143,49169.9%
2025-09-15108,2158167,20964.7%
2025-09-12150,5880185,35281.2%
2025-09-11108,5000160,95467.4%
2025-09-10201,7484256,59178.6%
2025-09-09113,1303,850173,14165.3%
2025-09-08300,5680543,09655.3%
2025-09-0562,6270127,57549.1%
2025-09-0472,7740124,26058.6%
2025-09-03139,0127192,01072.4%
2025-09-02134,713600469,88128.7%
2025-08-2996,0970154,98462.0%
2025-08-2864,104427157,84140.6%
2025-08-2771,1320106,01967.1%
2025-08-2668,5260161,22542.5%
2025-08-25108,7770228,04547.7%
2025-08-22130,1430306,02542.5%
2025-08-21294,442197430,01968.5%
2025-08-20123,4560399,02930.9%
2025-08-19154,1980420,30336.7%
2025-08-18188,2580281,40766.9%
2025-08-15120,890500169,13371.5%
2025-08-14223,167250343,55665.0%
2025-08-13429,5006,636623,02468.9%
2025-08-1292,8890187,37349.6%
2025-08-11111,9610435,05325.7%
2025-08-08174,4530295,06259.1%
2025-08-07162,1620434,94437.3%
2025-08-06256,764152527,30048.7%
2025-08-05300,4575,008552,27054.4%
2025-08-0497,018161135,16471.8%
2025-08-01132,8910198,03567.1%
2025-07-31128,2370240,62353.3%
2025-07-30163,1985,000202,60780.5%
2025-07-29230,3770289,25179.6%
2025-07-28304,9630376,50881.0%
2025-07-25539,33098679,52079.4%
2025-07-24190,419102253,75275.0%
2025-07-23203,3370255,55779.6%
2025-07-22111,092171168,25666.0%
2025-07-21147,4950242,90960.7%
2025-07-18218,615432359,52660.8%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.